Don't Expect the New Antibiotic Plazomicin to Be Added to Formulary
September 2018
You'll see the new aminoglycoside, plazomicin (Zemdri, ZEM-dree), promoted for carbapenem-resistant Enterobacteriaceae (CRE).
It works like other aminoglycosides and has the same side effects...nephrotoxicity, ototoxicity, etc.
The difference is that plazomicin isn't as affected by aminoglycoside-modifying enzymes...the most common cause of aminoglycoside resistance to E. coli and other Enterobacteriaceae.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote